Notice ID: ad98bf9ecf90496fa0581049d81a9905Award NoticeAwardedArchived
6505--F18 - Flutemetamol - Flyrcado
Awarded on March 10, 2026. Full description on SAM.gov.
Awarded tounder 36C25726D0056 (source: SAM.gov award notice)• $0
Overview
- Posted
- March 11, 2026
- Notice type
- Award Notice
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of Veterans Affairs
Notice details
- Office
- 257-NETWORK CONTRACT OFFICE 17 (36C257)
- Place of performance
- Delivery To: VA North Texas Health Care System
- Last updated
- Nov 2, 2026
- First published
- Last updated on SAM.gov
- Award date
- Mar 10, 2026
- Award amount (SAM.gov award notice)
- $0
Identifiers
- Solicitation number
- 36C25726Q0205
- Notice ID
- ad98bf9ecf90496fa0581049d81a9905
- Award number (PIID)
- 36C25726D0056
Description
Presolicitation Notice Notice of Intent to Award a Sole Source Procurement The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, intends to award a firm-fixed priced contract to Medi-Physics, Inc. for the procurement of the following item: 0001: Flyrcado (flurpiridaz F-18) Injection, Unit of Issue: EA (mCi), Qty.: 990 The proposed sole source procurement will be made with a price that has been established on GE Healthcare s VA NAC contract 36F79725D0214. GE Healthcare has stated that orders for Flyrcado must be placed as open market orders to Medi-Physics, Inc. This notice is not to be considered a request for quotations or proposals. No contract will be awarded based on offers received in response to this notice; however, all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 7 days from the publication of this notice, a contract or order will be issued to Cardinal Health without any further notice. The anticipated statutory authority permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1, only one responsible source and no other supplies or services will satisfy agency requirements.
Award Overview
Award Number
36C25726D0056
Award Amount (SAM.gov award notice)
$0
Award Date
Mar 10, 2026
Awardee
Awardee UEI
CETPVZL5RQS3
Awardee CAGE Code
1WVC6
Awardee Address
ARLINGTON HEIGHTS, IL 60004, IL
Line Item Number
0001
Original Solicitation
Notice ID: ad98bf9ecf90496fa0581049d81a9905
Posted Date: Mar 11, 2026
Original Response Deadline: Not specified
Task Orders Under This IDV
Top 10 by total obligated
- $257.8KSigned Mar 10, 2026
More From This Vendor
Top 5 most recent
- $349.0KSigned Nov 6, 2026
- $69.5KSigned Nov 4, 2026
- $83.5KSigned Nov 3, 2026
- $180.7KSigned Oct 26, 2026
- $152.8KSigned Oct 26, 2026
Contacts
Contracting Officer
Primary Contact
Documents
Lifecycle
- 3Version 3Award NoticeArchivedCurrent
6505--F18 - Flutemetamol - Flyrcado
Other notices for this solicitation
- Pre-SolicitationRelated noticeJan 6, 2026
6505--Notice of Intent to Sole Source Procurement - Flyrcado (F18 Flurpiridaz) Injection
- AwardedRelated noticeFeb 13, 2026
6505--Flyrcado F18 Flurpiridaz Radiopharmaceutical Injection
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Sources Sought Notice The Department of Veterans Affairs, Network Contracting Office (NCO) 17, is seeking sources for the following procurement: NETSPOT® Gallium Ga 68 Dotatate Injection Item (radiopharmaceutical) will be delivered to the VA North Texas Health Care System, 4500 S. Lancaster Rd., Dallas, TX 75216-7167. NCO 17 is seeking sources from firms that are capable of providing this item. Firms that can provide this item are encouraged to respond to the sources sought notice by contacting the point of contact. Capable firms must respond to the POC before the closing date and time of the notice to be considered. Capable firms must identify with their company name and are encouraged to provide a capabilities statement (if readily available) with their response. This notice is NOT a formal request for quote or proposals. No formal solicitation document exists at this time. The information in this notice is for information and planning purposes only and is not to be construed as a commitment by the government. No contract will be awarded from this notice. | - | Special Notice | 10/30/2026 |
Radiopharmaceutical microspheres for William Beaumont Army Medical Center (WBAMC), Fort Bliss, TX, to support ongoing selective internal radiation therapy (SIRT) for patients presenting with unresectable metastic liver tumores secondary to colorectal cancer. | - | Awarded | Open |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 10/26/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 08/27/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed: a. Atopy - Topical Agents Anzupgo Eucrisa Opzelura Vtama Zoryve b. Lung Cancer - METEX14 Tabrecta Tepmetko The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. | - | Solicitation | 10/01/2026 |
Additional Details
Solicitation Number
36C25726Q0205
Archive Date
Apr 11, 2026
Office Address
San Antonio, TX, 78240